Elanco Animal HealthELAN
ELAN
About: Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
Employees: 9,450
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
31% more call options, than puts
Call options by funds: $23.3M | Put options by funds: $17.8M
17% more first-time investments, than exits
New positions opened: 63 | Existing positions closed: 54
2.24% more ownership
Funds ownership: 96.75% [Q3] → 98.98% (+2.24%) [Q4]
1% more funds holding
Funds holding: 383 [Q3] → 386 (+3) [Q4]
1% more repeat investments, than reductions
Existing positions increased: 138 | Existing positions reduced: 137
16% less capital invested
Capital invested by funds: $7.02B [Q3] → $5.93B (-$1.09B) [Q4]
57% less funds holding in top 10
Funds holding in top 10: 7 [Q3] → 3 (-4) [Q4]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$12
27%
upside
Avg. target
$14.80
56%
upside
High target
$19
100%
upside
5 analyst ratings
3 positive
60%
2 neutral
40%
0 negative
0%
Stifel Jonathan Block 10% 1-year accuracy 2 / 20 met price target | 37%upside $13 | Buy Maintained | 14 Apr 2025 |
Piper Sandler David Westenberg 45% 1-year accuracy 19 / 42 met price target | 27%upside $12 | Neutral Maintained | 6 Mar 2025 |
UBS Andrea Alfonso 0% 1-year accuracy 0 / 2 met price target | 79%upside $17 | Buy Maintained | 26 Feb 2025 |
Morgan Stanley Erin Wright 54% 1-year accuracy 13 / 24 met price target | 37%upside $13 | Equal-Weight Maintained | 26 Feb 2025 |
Barclays Balaji Prasad 21% 1-year accuracy 9 / 43 met price target | 100%upside $19 | Overweight Maintained | 26 Feb 2025 |
Financial journalist opinion
Based on 18 articles about ELAN published over the past 30 days
Negative
Zacks Investment Research
10 hours ago
Earnings Preview: Elanco Animal Health Incorporated (ELAN) Q1 Earnings Expected to Decline
Elanco Animal Health (ELAN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
GlobeNewsWire
1 day ago
ELANCO ALERT: Bragar Eagel & Squire, P.C. is Investigating Elanco Animal Health Incorporated on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Elanco Animal Health Incorporated (NYSE:ELAN) on behalf of long-term stockholders following a class action complaint that was filed against Elanco on October 7, 2024 with a Class Period from November 7, 2023 to June 26, 2024. Our investigation concerns whether the board of directors of Elanco have breached their fiduciary duties to the company.
Neutral
Accesswire
1 day ago
Elanco Animal Health Incorporated (ELAN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / April 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN.
Neutral
Accesswire
6 days ago
Elanco Animal Health Incorporated (ELAN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / April 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN.
Neutral
CNBC Television
1 week ago
Trade Tracker: Sarat Sethi buys Zoetis and sells Elanco
Sarat Sethi, Managing Partner at DCLA, joins CNBC's "Halftime Report" to detail his latest trades.
Neutral
Accesswire
1 week ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Elanco Animal Health Incorporated (ELAN) And Encourages Investors to Connect
NEW YORK CITY, NY / ACCESS Newswire / April 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN.
Neutral
PRNewsWire
1 week ago
Elanco's Breakthrough Treatment for Deadly Canine Parvovirus Has Saved Thousands of Puppies, Reaffirms Commitment to Increasing the Availability of Canine Parvovirus Monoclonal Antibody for Second Annual National Parvo Awareness Day
National Parvo Awareness Day raises awareness of canine parvovirus (parvo), the often-fatal puppy disease. Elanco's Canine Parvovirus Monoclonal Antibody (CPMA) is the first-and-only USDA conditionally approved treatment for parvo.
Neutral
Accesswire
1 week ago
Bronstein, Gewirtz & Grossman, LLC Encourages Elanco Animal Health Incorporated (ELAN) Stockholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESS Newswire / April 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN.
Neutral
Accesswire
1 week ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elanco Animal Health Incorporated (ELAN) and Encourages Investors to Learn More About the Investigation
NEW YORK CITY, NY / ACCESS Newswire / April 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN.
Neutral
Accesswire
2 weeks ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Elanco Animal Health Incorporated (ELAN) And Encourages Stockholders to Connect
NEW YORK CITY, NY / ACCESS Newswire / April 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who purchased Elanco securities prior to November 7, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ELAN.
Charts implemented using Lightweight Charts™